Citation Impact
Citing Papers
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
2023 Standout
Nucleoside-modified VEGFC mRNA induces organ-specific lymphatic growth and reverses experimental lymphedema
2021 StandoutNobel
Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
2018
Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features
2019
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
2016 Standout
The Cardiovascular Biology of Glucagon-like Peptide-1
2016
Glucagon-Like Peptide-1 and Its Class B G Protein–Coupled Receptors: A Long March to Therapeutic Successes
2016
Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial
2018
Trends in GPCR drug discovery: new agents, targets and indications
2017 Standout
Efficacy and Acceptability of Glycemic Control of Glucagon-Like Peptide-1 Receptor Agonists among Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
2016
How May GIP Enhance the Therapeutic Efficacy of GLP-1?
2020
Mammalian display screening of diverse cystine-dense peptides for difficult to drug targets
2017 StandoutNobel
Type 2 diabetes
2017 Standout
Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial
2018
Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes – focus on pancreatitis and pancreas cancer
2014
The Discovery and Development of Liraglutide and Semaglutide
2019
Triple therapy combinations for the treatment of type 2 diabetes – A network meta-analysis
2016
Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies
2017
Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies
2017
Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research
2017
2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association
2021 Standout
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
2023 Standout
Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives
2015
Efficacy and safety of once‐weekly glucagon‐like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta‐analysis of randomized controlled trials
2015
Efficacy and safety of glucagon‐like peptide‐1 receptor agonists in type 2 diabetes: A systematic review and mixed‐treatment comparison analysis
2016
Tirzepatide Once Weekly for the Treatment of Obesity
2022 Standout
Benefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments
2015
Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon‐like peptide‐1 receptor agonists: A systematic analysis of published clinical trials
2016
Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
2017
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
2018 Standout
Once-Weekly Semaglutide in Adults with Overweight or Obesity
2021 Standout
GLP-1 receptor agonists: an updated review of head-to-head clinical studies
2021
GLP-1 receptor agonists: a review of head-to-head clinical studies
2014
Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial
2016
Incretin therapies: highlighting common features and differences in the modes of action of glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors
2015
MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?
2019
Works of Charles Atisso being referenced
Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)
2014
Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events
2016
Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial
2014